前沿交联生物材料推动眼科治疗进展
综述总结当代眼科交联方法的机制与分类,评估角膜与巩膜交联的临床及实验结局。重点讨论纳米颗粒、水凝胶和微针系统等生物材料在提高基质渗透、控释和降低侵入性方面的进展,并指出治疗深度一致性、长期生物安全性和临床结局稳定性仍是关键挑战。
要点
- 角膜交联(CXL)从圆锥角膜扩展至多种角膜扩张和感染性疾病,巩膜加固用于进展性近视受关注。
- 纳米颗粒、水凝胶和微针系统等生物材料用于增强基质渗透、控释和降低侵入性。
- 治疗深度一致性、长期生物安全性和临床结局稳定性仍是当前方案的主要挑战。
核心结论
- 眼科交联技术通过优化试剂配方、递送策略和功能生物材料取得进展,但治疗深度一致性、长期生物安全性和临床结局稳定性仍是关键挑战。
研究设计与样本
- 综述总结当代眼科交联方法与制剂的机制和分类,评估角膜与巩膜交联的临床和实验结局及其优缺点。
主要发现
- 角膜交联(CXL)最初用于减缓或阻止圆锥角膜(KC)进展,适应症已扩展至多种角膜扩张和感染性疾病。
- 巩膜加固用于进展性近视受到越来越多的关注。
- 纳米颗粒、水凝胶和微针系统等生物材料可增强基质渗透、实现控释并降低操作侵入性。
临床怎么用
- 综述为开发下一代眼科交联疗法提供概念框架,强调提高治疗精度、安全性和可重复性的新兴策略。
局限性
- 实现一致的治疗深度、维持长期生物安全性和确保稳定的临床结局仍是关键挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Corneal cross-linking (CXL) has emerged as an important therapeutic strategy for enhancing the biomechanical stability of corneal tissues. Originally introduced to slow or halt the progression of keratoconus (KC), its indications have expanded to include a variety of corneal ectatic and infectious disorders, alongside a growing interest in scleral reinforcement for progressive myopia. Recent advances in cross-linking technologies focused on optimizing reagent formulations, refining delivery strategies, and incorporating functional biomaterials such as nanoparticles, hydrogels, and microneedle-based systems to enhance stromal penetration, achieve controlled release, and reduce procedural invasiveness. Despite these developments, key challenges remain, particularly in achieving consistent treatment depth, maintaining long-term biosafety, and ensuring stable clinical outcomes. This review summarizes the mechanisms of action and classification of contemporary ophthalmic cross-linking methods and agents, evaluating their clinical and experimental outcomes in corneal and scleral cross-linking while weighing their respective strengths and limitations. Furthermore, this review identifies key constraints of current protocols and highlights emerging strategies aimed at improving treatment precision, safety, and reproducibility, thereby providing a conceptual framework for the development of next-generation ophthalmic cross-linking therapies.
引用
- Ning R, Fu X, Chen L, et al. Cutting-edge cross-linking biomaterials advancing ophthalmic therapeutics. Prog Retin Eye Res. 2026. PMID: 42320844. doi:10.1016/j.preteyeres.2026.101489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。